StockUS listing USELANNYSEHealthcareProfitless Growth

Elanco Animal Health(ELAN) Stock Analysis | Healthcare

USD --+0.00%
Reward41Moderate
Risk64Medium-High
75%Data
Thin -4% profit margin · Revenue growing 10% YoY
USD —+0.00 (+0.00%) Previous close · NYSE
Market cap 11.45Bn
Reward Ratingⓘ41 Moderate reward assessment · 75% data coverage
Bottom 10% of stocksView factors
Risk Ratingⓘ64 Medium-High risk assessment
Risk factors availableUnlock details

Educational tool only – Scores are based on historical data and financial metrics for informational purposes. This is not financial advice or a recommendation to buy or sell any security. Always conduct your own research or consult a qualified financial adviser.

Educational tool only · More
Limited data coverage
We don't have enough public data on ELAN to score it reliably yet — Reward, Risk, Forecasts and Dividends tabs aren't available for this stock. The price chart and basic profile are still shown.
OTC / ADR stock — scores and fundamentals use data tagged in USD by our provider. The issuer may report in a different home currency (e.g. JPY), so treat figures as directional rather than precise.
Not available yet for this stock
The overview tab requires data we don't have for this stock yet. The price chart is the most reliable view we have — try the Chart tab.
Earnings Ex-dividend

Market Performance

Stock returned +10.0% over the past year, broadly in line with market conditions.

What is Elanco Animal Health?

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide.

AI Brief Pro

The brief on Elanco Animal Health

The story behind the price, the case for and against, and what could go wrong. Open a part to read it.

What is Elanco Animal Health?

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals worldwide. The company offers pet health products, such as parasiticides, vaccines, and therapeutics that protect pets from fleas, ticks, and internal parasites under the Seresto, K-9 Advantage, Advantix, and Advocate trademarks; prescription parasiticide products, an over-the-counter treatments for the prevention and elimination of fleas and ticks under the Credelio Family, Interceptor Plus, Drontal family, and Drontal Plus; vaccines portfolio that provides differentiated prevention coverage for a number of important pet health risks; and therapeutics portfolio for the treatment of pain, otitis, cardiovascular, and dermatology indications, as well as osteoarthritis for dogs and cats under the Galliprant trademark. The company is listed on the NYSE in USA, operating in the Healthcare sector, with a market capitalisation of 11.45B.

Financial Highlights

Investment Breakdown

Growth
Revenue and earnings growing steadily, indicating improving operating performance.
Profitability
Thin or inconsistent margins weigh on earnings quality.
Risk
Moderate volatility with meaningful macro and earnings sensitivity.
Valuation
Valuation is less clear with a negative earnings base.

OpenBook Logo Analysis

Reward: Moderate (41)

Similar stocks to compare

A short list of Drug Manufacturers - Specialty & Generic names that are close enough in size to make side-by-side comparison useful.

Company Information
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Beta1.705
Insider Activity
12M windowBullish
Shares soldShares bought
0-3months
0
0
3-6months
0
0
6-9months
0
0
9-12months
0
443,450 shares
$938k